JAVIER
SASTRE VALERA
Profesor asociado de Ciencias de la Salud
Hospital Clínico Universitario Lozano Blesa
Zaragoza, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico Universitario Lozano Blesa (17)
2022
-
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210
2019
2018
-
Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer
International Journal of Cancer, Vol. 143, Núm. 8, pp. 1954-1962
2017
-
Prognostic significance of venous thromboembolic events in disseminated germ cell cancer patients
Journal of the National Cancer Institute, Vol. 109, Núm. 4
2015
-
A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: Clinical and biological features
BMC Cancer, Vol. 15, Núm. 1
-
Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer
Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541
2014
-
Prognostic factors for relapse in stage I seminoma: A new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)
Annals of Oncology, Vol. 25, Núm. 11, pp. 2173-2178
-
Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base
Clinical and Translational Oncology, Vol. 16, Núm. 11, pp. 959-965
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
2011
-
Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines
Clinical and Translational Oncology, Vol. 13, Núm. 8, pp. 536-544
-
SEOM clinical guidelines for diagnosis and treatment of testicular seminoma (2010)
Clinical and Translational Oncology, Vol. 13, Núm. 8, pp. 560-564
-
SEOM guidelines: Non-seminomatous germ cell cancer (NSGCC)
Clinical and Translational Oncology, Vol. 13, Núm. 8, pp. 565-568
2010
-
SEOM clinical guidelines for the adjuvant treatment of colorectal cancer
Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 724-728
2003
-
Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma
Annals of Oncology, Vol. 14, Núm. 6, pp. 867-872